---
layout: post
title: "Withdrawal of Approval of Five Abbreviated New Drug Applications for Bacitracin for Injection"
date: 2026-02-05 19:08:48 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-05105
original_published: 2021-03-12 00:00:00 +0000
significance: 8.00
---

# Withdrawal of Approval of Five Abbreviated New Drug Applications for Bacitracin for Injection

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 12, 2021 00:00 UTC
**Document Number:** 2021-05105

## Summary

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is withdrawing approval of five abbreviated new drug applications (ANDAs) from multiple holders. Akorn Inc. (Akorn), Mylan ASI LLC (Mylan), Pfizer Inc. (Pfizer), X-GEN Pharmaceuticals, Inc. (X-GEN), and Fresenius Kabi USA, LLC (Fresenius) have requested withdrawal of approval of their respective applications and have waived their opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/12/2021-05105/withdrawal-of-approval-of-five-abbreviated-new-drug-applications-for-bacitracin-for-injection)
- API: https://www.federalregister.gov/api/v1/documents/2021-05105

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
